DUPIXENT does NOT have any known drug-to-drug interactions.1 DUPIXENT is NOT metabolized through the liver or excreted through the kidneys.1

In the DUPIXENT pivotal clinical trials, the most common adverse reactions (incidence ≥1%) in patients with atopic dermatitis were injection site reactions, conjunctivitis, blepharitis, oral herpes, keratitis, eye pruritus, other herpes simplex virus infection, dry eye, and eosinophilia. The safety profile of DUPIXENT in pediatric patients 6 months to 17 years of age through Week 16 was similar to the safety profile from studies in adults with atopic dermatitis. In an open-label extension study (AD-1434), the safety profile of DUPIXENT ± TCS in pediatric patients observed through Week 52 was consistent with that seen in adults with atopic dermatitis. In AD-1434, hand-foot-and-mouth disease and skin papilloma (incidence ≥2%) was reported in patients 6 months to 5 years of age. These cases did not lead to study drug discontinuation.1

Please see additional Warnings and Precautions in the Prescribing Information and Important Safety Information throughout.